Drug intelligence / Profile preview

pifithrin

Development stage
Preclinical
Lead developer
Quark Pharmaceuticals
Modality
Small Molecules
Administration
Intraperitoneal, Intravenous, Oral, Parenteral
01

Overview

Pifithrin is a small molecule inhibitor of the tumor suppressor protein p53 (TP53). It was originally identified for its ability to protect cells from p53-mediated apoptosis induced by DNA-damaging agents or radiation. Pifithrin-alpha, the most common analog, acts by reversibly inhibiting p53-dependent transcriptional activity and mitochondrial translocation. While widely used as a research tool to investigate p53 signaling pathways in various models, including cancer and neuroprotection, it has not reached clinical approval. In the context of oncology research, it is often used to validate the role of p53 in suppressing endogenous retroviruses or to model p53-deficient states in cell lines.

Other names
pifithrin-alpha2-(2-Imino-4,5,6,7-tetrahydrobenzothiazol-3-yl)-1-p-tolylethanone
02

Targets

GR (Glucocorticoid receptor)TP53 (Cellular Tumor Antigen p53 R175H)HSF1 (Heat shock factor 1)AHR (Aryl hydrocarbon receptor)

Beyond the preview

Go deeper on pifithrin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pifithrin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call